Pathstone Holdings
OGEN icon

Pathstone Holdings’s Oragenics OGEN Stock Holding History

Pathstone Holdings’s Portfolio OGEN Stock Details OGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.8K Buy
+55,001
New +$43.5K ﹤0.01% 2199

Other funds holding OGEN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
AAS
Ameritas Advisory Services Lincoln, Nebraska $2.58B AUM 18.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SJIM
St. Johns Investment Management Jacksonville, Florida $238M AUM 22.04% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Pathstone Holdings's OGEN Position: Q1 2026 in Review

Pathstone Holdings opened a new position in Oragenics (OGEN) in Q1 2026: 55,001 shares worth $30.8K. The stake represents ﹤0.01% of the portfolio and ranks #2199 among its holdings.

19 funds tracked by Wall St. Rank hold OGEN as of Q1 2026.

  • Pathstone Holdings held 55,001 shares of Oragenics worth $30.8K as of Q1 2026.
  • Oragenics was a new Pathstone Holdings position in Q1 2026.
  • Oragenics made up ﹤0.01% of Pathstone Holdings's portfolio in Q1 2026, its #2199 holding.
  • 19 funds tracked by Wall St. Rank held Oragenics as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.